- Home
- TSHA vs TSSI Comparison
TSHA vs TSSI Comparison
Compare TSHA & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- TSSI
- Stock Information
- Founded
- TSHA 2019
- TSSI 2004
- Country
- TSHA United States
- TSSI United States
- Employees
- TSHA N/A
- TSSI N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- TSSI Professional Services
- Sector
- TSHA Health Care
- TSSI Consumer Discretionary
- Exchange
- TSHA Nasdaq
- TSSI Nasdaq
- Market Cap
- TSHA 397.8M
- TSSI 353.7M
- IPO Year
- TSHA 2020
- TSSI N/A
- Fundamental
- Price
- TSHA $2.13
- TSSI $7.33
- Analyst Decision
- TSHA Strong Buy
- TSSI
- Analyst Count
- TSHA 8
- TSSI 0
- Target Price
- TSHA $6.63
- TSSI N/A
- AVG Volume (30 Days)
- TSHA 3.0M
- TSSI 647.5K
- Earning Date
- TSHA 05-16-2025
- TSSI 05-15-2025
- Dividend Yield
- TSHA N/A
- TSSI N/A
- EPS Growth
- TSHA N/A
- TSSI 7042.86
- EPS
- TSHA N/A
- TSSI 0.24
- Revenue
- TSHA $8,333,000.00
- TSSI $148,144,000.00
- Revenue This Year
- TSHA N/A
- TSSI N/A
- Revenue Next Year
- TSHA N/A
- TSSI N/A
- P/E Ratio
- TSHA N/A
- TSSI $30.54
- Revenue Growth
- TSHA N/A
- TSSI 172.33
- 52 Week Low
- TSHA $1.05
- TSSI $0.88
- 52 Week High
- TSHA $4.32
- TSSI $18.26
- Technical
- Relative Strength Index (RSI)
- TSHA 58.69
- TSSI N/A
- Support Level
- TSHA $1.85
- TSSI N/A
- Resistance Level
- TSHA $2.28
- TSSI N/A
- Average True Range (ATR)
- TSHA 0.26
- TSSI 0.00
- MACD
- TSHA 0.03
- TSSI 0.00
- Stochastic Oscillator
- TSHA 52.96
- TSSI 0.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TSSI TSS Inc. Common Stock
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: facilities, and systems integration. It generates the majority of its revenue from Systems integration services. It generates revenue from the United States.